Introduction
HER2-positive MBC, HER2-positive metastatic breast cancer
Human epidermal growth factor receptor 2 (HER2) targeted therapy combined with chemotherapy is the established first-line approach for treating HER2-positive metastatic breast cancer (MBC)Pyrotinib is a small molecule TKI that targets HER1, HER2, and HER4In this work, we assess the efficacy and safety of pyrotinib plus docetaxel as a first-line treatment for HER2-positive MBC. Our findings demonstrate that the combination of pyrotinib with docetaxel shows promising antitumor activity and offers a PFS benefit in the first-line treatment of patients with HER2-positive MBC.